Melchor Riera
YOU?
Author Swipe
View article: Planetary health diet, other plant-based diets and risk of type 2 diabetes: a prospective study from the UK Biobank
Planetary health diet, other plant-based diets and risk of type 2 diabetes: a prospective study from the UK Biobank Open
In this large cohort of British adults, higher adherence to the PHDI was associated with a substantially lower risk of type 2 diabetes, with effect sizes comparable to or greater than those observed for other well-known PBDs. These finding…
View article: Real-World Application of Trio-Based Exome Sequencing in Prenatal Genetic Diagnosis: a prospective study
Real-World Application of Trio-Based Exome Sequencing in Prenatal Genetic Diagnosis: a prospective study Open
View article: Association between the Planetary Health Diet Index and growth differentiation factor-15: the Seniors ENRICA-2 cohort
Association between the Planetary Health Diet Index and growth differentiation factor-15: the Seniors ENRICA-2 cohort Open
View article: Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks Open
Objectives To evaluate the long-term effectiveness, persistence and tolerability of dolutegravir (DTG)/lamivudine (3TC), compared with the most frequently prescribed first-line treatment regimens, among antiretroviral-naive people with HIV…
View article: Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters Open
Our results suggest that BIC/FTC/TAF could be a preferred regimen as initial therapy in HIV late presenters because of its high effectiveness and good tolerability.
View article: Correction: Syndemic conditions and quality of life in the PISCIS Cohort of people living with HIV in Catalonia and the Balearic Islands: a cross sectional study
Correction: Syndemic conditions and quality of life in the PISCIS Cohort of people living with HIV in Catalonia and the Balearic Islands: a cross sectional study Open
View article: Syndemic conditions and quality of life in the PISCIS Cohort of people living with HIV in Catalonia and the Balearic Islands: a cross sectional study
Syndemic conditions and quality of life in the PISCIS Cohort of people living with HIV in Catalonia and the Balearic Islands: a cross sectional study Open
View article: Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study Open
View article: Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study Open
View article: Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review Open
View article: Additional file 2 of Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review
Additional file 2 of Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review Open
Additional file 2. List and details of included papers.
View article: Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study Open
View article: Correction: Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017
Correction: Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017 Open
[This corrects the article DOI: 10.1371/journal.pone.0204738.].
View article: Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort
Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort Open
Objectives The aim of the study was to assess the rates of discontinuation of integrase inhibitor regimens because of any neuropsychiatric adverse event (NPAE) and the factors associated with discontinuation. Methods A population‐based, pr…
View article: HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation
HIV-Infected Subjects With Poor CD4 T-Cell Recovery Despite Effective Therapy Express High Levels of OX40 and α4β7 on CD4 T-Cells Prior Therapy Initiation Open
Our results are compatible with exacerbated HP processes in immunodiscordant subjects, already before the cART onset.
View article: Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) Open
The long-term results of switching to ATV/r + 3TC show that this strategy is effective, safe and non-inferior to ATV + 2NUCs in virologically suppressed HIV-infected patients.